Ascendis Unveils Key Achondroplasia Trial Data at ICCBH 2026
Ascendis Pharma just dropped significant new clinical data on its achondroplasia treatments, YUVIWEL and a combination of YUVIWEL and SKYTROFA, at the ongoing International Conference on Children's Bone Health (ICCBH) in Montreal. This highly anticipated presentation includes detailed 104-week results from the pivotal ApproACh trial for YUVIWEL and 52-week data from the Phase 2 COACH trial evaluating the combination approach, offering crucial insights into improving outcomes for children with this rare genetic condition.

















